University of California San Francisco

Alexander Murphy, MD

Alexander Murphy
Alexander Murphy, MD

Resident Research Fellow
Plastic Surgery

[email protected]

Education

Institution Degree Dept or School End Date
Columbia University MD 05/2022
University of Pennsylvania BA 05/2016

Publications

MOST RECENT PUBLICATIONS FROM A TOTAL OF 10
  1. Two-Year Outcomes Following Delandistrogene Moxeparvovec Treatment in Ambulatory Patients with Duchenne Muscular Dystrophy: Phase 3 EMBARK Trial.
    Mendell JR, Muntoni F, McDonald CM, Mercuri EM, Ciafaloni E, Komaki H, Leon-Astudillo C, Nascimento A, Proud C, Schara-Schmidt U, Veerapandiyan A, Zaidman CM, Furgerson M, Ding K, Singh P, Potter R, Asher DR, Murphy AP, Reid C, Hooper G, Torre CO, Manfrini M, Rodino-Klapac LR| | PubMed
  2. Immunologic investigations into transgene directed immune-mediated myositis following delandistrogene moxeparvovec gene therapy.
    Potter RA, Moeller IH, Khan S, Haegel H, Hollenstein A, Steiner G, Wandel C, Murphy AP, Asher DR, Palatinsky E, Griffin DA, Mason S, Iannaccone ST, Zaidman CM, Rodino-Klapac LR| | PubMed
  3. Caregiver Global Impression Observations from EMBARK: A Phase 3 Study Evaluating Delandistrogene Moxeparvovec in Ambulatory Patients with Duchenne Muscular Dystrophy.
    McDonald CM, Elkins JS, Dharmarajan S, Gooch K, Ciobanu T, Lansdall CJ, Murphy AP, McDougall F, Mercuri EM, Audhya I, EMBARK Study Group| | PubMed
  4. AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial.
    Mendell JR, Muntoni F, McDonald CM, Mercuri EM, Ciafaloni E, Komaki H, Leon-Astudillo C, Nascimento A, Proud C, Schara-Schmidt U, Veerapandiyan A, Zaidman CM, Guridi M, Murphy AP, Reid C, Wandel C, Asher DR, Darton E, Mason S, Potter RA, Singh T, Zhang W, Fontoura P, Elkins JS, Rodino-Klapac LR| | PubMed
  5. The Devil's in the Depot Details: Case of Iatrogenic Opioid Intoxication After Buprenorphine Injection Requiring Surgical Excision.
    Vais S, Starr N, Castro M, Brand N, Murphy A, Tesoriero R, Kryzhanovskaya I| | PubMed
  6. Reply: Lymphatic Microsurgical Preventative Healing Approach for the Primary Prevention of Lymphedema: A 4-Year Follow-Up.
    Murphy AI, O'Connell GM, Ishtihar S, Levy AS, Rohde CH| | PubMed
  7. Functional donor-site morbidity following reconstruction with pectoralis major flaps: A systematic review.
    Falade IO, Murphy AI, Switalla KM, Yin RR, Rose JA| | PubMed
  8. Practical Considerations for Delandistrogene Moxeparvovec Gene Therapy in Patients With Duchenne Muscular Dystrophy.
    Mendell JR, Proud C, Zaidman CM, Mason S, Darton E, Wang S, Wandel C, Murphy AP, Mercuri E, Muntoni F, McDonald CM| | PubMed
  9. Delandistrogene Moxeparvovec Gene Therapy in Ambulatory Patients (Aged ≥4 to <8 Years) with Duchenne Muscular Dystrophy: 1-Year Interim Results from Study SRP-9001-103 (ENDEAVOR).
    Zaidman CM, Proud CM, McDonald CM, Lehman KJ, Goedeker NL, Mason S, Murphy AP, Guridi M, Wang S, Reid C, Darton E, Wandel C, Lewis S, Malhotra J, Griffin DA, Potter RA, Rodino-Klapac LR, Mendell JR| | PubMed
  10. Closing the Gap: Training Experiences and Career Outcomes for Underrepresented Minorities in Plastic Surgery.
    Diatta F, Mellia JA, Morris MP, Murphy AI, Onyekaba G, Mares J, McAuliffe PB, Broach RB, Fischer JP, Butler PD| | PubMed